XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Peer Review reports

Original Submission
4 Sep 2011	Submitted	Original manuscript
14 Jan 2012	Reviewed	Reviewer Report - Lara Lipton
4 Apr 2012	Reviewed	Reviewer Report - Wei Chua
6 May 2012	Author responded	Author comments - George Papaxoinis
Resubmission - Version 2
6 May 2012	Submitted	Manuscript version 2
Publishing
29 Jun 2012	Editorially accepted
29 Jun 2012	Article published	10.1186/1471-2407-12-271

Back to article page